Boryung, HK inno.N to co-market Kanarb, K-CAB
This is the first collaboration between the two S.Korean companies that have created blockbuster new drugs
By Dec 20, 2023 (Gmt+09:00)
S.Korea's LS Materials set to boost earnings ahead of IPO process
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
NPS to cut global stocks under GP management, up its direct control
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Korean PE funds shrink in 2023 for first time in 7 years
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
Galaxy Ring, new foldables set to steal the show at Samsung Unpacked Paris
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
POSCO gears up for carbon-free steelmaking with hydrogen
![close](/images/ico/eyes/close.png)
![open](/images/ico/eyes/open.png)
![Boryung, HK inno.N to co-market Kanarb, K-CAB](https://www.kedglobal.com/data/ked/image/2023/12/20/ked202312200028.647x.0.jpg)
South Korea’s pharmaceutical companies Boryung Corp. and HK inno.N announced on Wednesday that they will start co-marketing for their respective blockbuster drugs Kanarb and K-CAB in January next year.
This deal is the first collaboration between domestic pharmaceutical companies that have developed blockbuster new drugs with annual sales exceeding 100 billion won ($76.98 million).
Under the agreement, Boryung will take over marketing for all K-CAB products, including tablets and orally disintegrating tablets. HK inno.N will manage the four types of Kanarb: Kanarb, Dukaro, Dukarb, and Dukarb Plus.
Medical Market research firm UBIST reports that K-CAB, a treatment for gastroesophageal reflux disease, recorded sales of 132.1 billion won ($101 million) last year. Meanwhile, Kanarb, a hypertension treatment, generated 150.3 billion won ($115 million) in 2022 across seven product variations.
Write to Ji-Hyun Lee at bluesky@hankyung.com
-
Bio & PharmaHK inno.N reveals differentiated clinical results for K-CAB
Dec 12, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaS.Korea's Boryung gets gov’t OK for diabetes drug Trubuddy
Sep 06, 2023 (Gmt+09:00)
1 Min read -
-
Mergers & AcquisitionsDongwon backs out of Boryung Biopharma buyout deal
Mar 23, 2023 (Gmt+09:00)
1 Min read -
Bio & PharmaBoryung, Axiom Space to set up JV to explore space healthcare options
Mar 21, 2023 (Gmt+09:00)
3 Min read -
Bio & PharmaHK inno.N's GERD drug K-CAB gets approval in Mexico
Feb 14, 2023 (Gmt+09:00)
1 Min read